Clinical Pharmacists – exploring the scope, capabilities, and potential of this evolving NHS role

Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.

Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?

In this episode, our experts in HTA, health economics, and commercialisation explore:
- How to identify and communicate the value of your product for patients and the wider healthcare system
- How to build a robust evidence package for successful launch and commercialisation
- Key requirements for the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) or Diagnostics Assessment Programme (DAP)
- Next steps to take your innovation to healthcare leaders across the NHS and beyond, with an impactful customer communication strategy

This episode was first broadcast as a live webinar in January 2023. Learn more and request a copy of the slides at: https://mtechaccess.co.uk/evidence-strategy-for-medical-technologies-and-diagnostics/

Discover how Mtech Access can support your commercialisation journey at: https://mtechaccess.co.uk/medical-device-market-access/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.

Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best support overarching product and brand strategy, with a focus on launch challenges in the US market.

We take a step back from the intricacies of market access and HEOR, to explore the role our specialism plays in broader commercial and product strategy. We ask: where does market access and HEOR sit in this broader picture, and how can market access teams best support their product and company brand?

Using the US market as our case study, we explore:

- How to set up your product for success
- Commercialisation routes in the US for Pharma and Medtech
- The relationship between brand strategy and market access
- What Pharma can learn from Medtech’s approach to commercialisation
- What Medtech innovators can learn from Pharma companies’ approach to launch

This episode was first broadcast as a live webinar in January 2024.

Learn more at: https://mtechaccess.co.uk/commercialisation-strategy-us-market/

Explore our work in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/

Discover how Mtech Access can support you global market access and pricing strategy: https://mtechaccess.co.uk/global-market-access-and-pricing/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?

Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.

Malcolm Qualie and David Thorne explored:

• Specialised commissioning in the NHS
• The risks and opportunities that devolution to ICBs will bring
• What we can expect to see in the short and longer term
• How industry can support ICB leaders through this transition
• How Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties

Learn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/

This episode first broadcast as a live webinar in Decmeber 2023. 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?

Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and the lessons England can take from the Welsh experience.

In this NHS Whispers webinar, guest speaker Paul Mears shares his experiences leading a Welsh health board. The 7 Health Boards in Wales have been operating as integrated systems for over a decade. With the NHS in England just getting to grips with integration, we explore what England can learn from the Welsh experience.

Robert and Paul explore:
 - How NHS Wales is structured and who the key decision makers are
 - How the integrated healthcare system works in Wales and how this differs to what’s happening in England
 - How priorities are set and what shapes decision-making at health board level
 - The nuances of the Welsh health system and what this means for industry
 - How Welsh Health Boards work with industry and the lessons here for ICBs and industry in England
 - Prudent healthcare and what this means in practice
 - How industry can best engage with health board leaders, what channels to use, and what messages to bring

This episode was first broadcast live as webinar in November 2023

Learn more about this webinar at: https://mtechaccess.co.uk/integrated-care-in-nhs-wales/

Discover how we can help you with your NHS engagement and UK market access strategy at: https://mtechaccess.co.uk/uk-nhs-insights/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).

We explore:
- The nature of the Italian market and the reimbursement process
- Pricing and market access considerations when launching in Italy
- What the reforms at AIFA mean for market access and managed entry agreements
- How the AIFA changes specifically impact innovative products
- Changes to early access programmes in Italy
- Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)

This episode was first broadcast as a live webinar in October 2023. Learn more at: https://mtechaccess.co.uk/italy-market-access-aifa-reforms/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond.

Former ‘GP of the year’ and strategic influencer over primary care policy, Dr Farzana Hussain, discusses the unmet needs in primary care, how primary care leaders are responding to these challenges, and where industry can best offer support.

Phil and Farzana discuss:

•  How unmet needs are identified in primary care, the processes followed, and datasets used to inform decision making
•  The specific challenges facing primary care as we head into winter
•  The role of PCN leaders and their impact on national policy
•  How industry can best support and collaborate with PCNs
•  Ongoing lessons from the pandemic and the vaccine roll-out

Learn more about this webinar at: https://mtechaccess.co.uk/unmet-need-nhs-primary-care/

Discover or NHS Insight and UK market access services: https://mtechaccess.co.uk/uk-nhs-insights/

This episode was first broadcast as a live webinar in October 2023. 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

How can our community support NHS leaders to deliver a data-led, people-centric health service?

Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support the NHS’s population health management goals.

Population health management has the potential to be a powerful tool for healthcare systems, effecting the way health and care is strategised, budgeted, targeted, and delivered. We see a future where key decisions in the NHS are driven by population health data. What we now need is a new way of working powered by local need, quality evidence and a systematic approach.

In this webinar, Phil and Mark explore:

 - How the NHS can use population health management to transform the system
 - The importance of community in population health management
 - How Pharma, Medtech, and the wider life sciences sector can work above brand to support the NHS with population health management
 - What a data-driven, people-centric approach means for the way treatments are valued
 - How population health management could transform the economics of healthcare

This episode was first broadcast as a live webinar on Friday 8th September 2023. Learn more at: https://mtechaccess.co.uk/uk-nhs-insights/

Discover more about our work in this area at: https://mtechaccess.co.uk/uk-nhs-insights/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?

In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:

- How, when and where AI is being used in clinical trials
- How Lexitas are using AI in clinical trials for ophthalmology
- Where AI may offer solutions to existing obstacles in clinical trials and ophthalmic drug development
- What the future holds for AI in the development of new medicines
- The role AI can play in selecting patients for clinical trials
- The impact AI may have on the way we evaluate drug effectiveness
- What this all means for evidence synthesis, health economics, reimbursement and market access
- The future prospects of AI in pharmaceutical development

Learn more at: https://mtechaccess.co.uk/ai-clinical-trials-evidence/

This episode was first broadcast as a live webinar in August 2023. 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators?

Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its implications for Medtech, Health technologies, and Medical Device market access.

With the challenges of the pandemic and the changes brought in following Brexit, policy and compliance in the UK has been on shifting sands for several years now. With many predicting a change in government at the next election, this continues to be a time of uncertainty. What does this political landscape mean for health policy, the regulatory regime and market access?

In this on-demand webinar, Rob asks Bill about 6 areas where Medtech should be paying attention:

• MHRA and new medical device regulatory regime
• UK health and social care supply and procurement
• Sustainability and social value
• Addressing capacity challenges with effective health and social care packages
• Innovation
• Export and import – the implications of Brexit

This episode was first broadcast as a live webinar in July 2023.  Learn more about this webinar at:  https://mtechaccess.co.uk/uk-health-policy-medtech-bhta-webinar/

Learn more about our services for Medtech companies at: https://mtechaccess.co.uk/medical-device-market-access/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Here we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets.

Clare and Stefan discuss:
 - Preparing for access to Switzerland – a European market outside the EU
 - Pricing strategy and HTA decision-making in Austria under the new Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
 - Launching in Germany – is this still one of the most attractive European markets?
 - The Financial Stabilisation Act in Germany – what this means for drug pricing

Learn more at: https://mtechaccess.co.uk/market-acce...

This episode was first broadcast as a live webinar in July 2023. 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.